Compare ServiceNow Inc (NOW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? ServiceNow Inc trades at $126.73 (market cap $129.11B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: ServiceNow Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| NOW | VRTX | |
|---|---|---|
Market Cap | $129.11B | $132.79B |
Sector | Technology | Health |
52-Week High | $192.23 | $529.59 |
52-Week Low | $83.00 | $374.46 |
Enterprise Value | $132.90B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $127.54, up 2.13% with strong technical momentum. The stock shows robust fundamentals with 2025 revenue reaching $13.28B and net income of $1.75B, though valuation ratios remain elevated (P/E 78.05). Recent earnings performance has been mixed with Q2 2026 beating expectations but Q1 missing. Technical indicators show bullish moving averages but overbought RSI signals. The company maintains strong analyst support with 87% buy ratings and a $138.26 consensus target.
ServiceNow presents a compelling growth story with AI-driven expansion opportunities, though premium valuation requires careful risk assessment. Key risks include competitive pressures in enterprise software and execution challenges in maintaining high growth rates. The stock's current technical overbought condition suggests potential near-term consolidation before further upside potential toward analyst targets.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
